EGFR and pancreatic neoplasm: Furthermore, lower expression levels of p-EGFR, p-PI3K and p-AKT were observed when combined with Rg3, which revealed that Rg3 downregulates expressions of p-EGFR, p-PI3K, and p-AKT, thereby sensitizing pancreatic cancer cells to erlotinib.